What is Zacks Research’s Forecast for WST FY2025 Earnings?

West Pharmaceutical Services, Inc. (NYSE:WST) – Zacks Research boosted their FY2025 earnings per share (EPS) estimates for West Pharmaceutical Services in a research report issued to clients and investors on Thursday, August 14th. Zacks Research analyst Team now expects that the medical instruments supplier will post earnings per share of $6.67 for the year, up from their previous forecast of $6.26. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share. Zacks Research also issued estimates for West Pharmaceutical Services’ Q1 2026 earnings at $1.56 EPS, Q2 2026 earnings at $1.90 EPS, Q3 2026 earnings at $1.82 EPS, Q4 2026 earnings at $1.85 EPS, FY2026 earnings at $7.12 EPS and FY2027 earnings at $8.32 EPS.

WST has been the subject of several other research reports. Barclays assumed coverage on West Pharmaceutical Services in a research note on Tuesday, June 24th. They issued an “equal weight” rating and a $245.00 price target for the company. Evercore ISI boosted their price objective on West Pharmaceutical Services from $275.00 to $350.00 and gave the company an “outperform” rating in a research report on Friday, July 25th. UBS Group upped their target price on West Pharmaceutical Services from $285.00 to $320.00 and gave the stock a “buy” rating in a research note on Friday, July 25th. Stephens upgraded West Pharmaceutical Services to a “strong-buy” rating in a research report on Monday, April 21st. Finally, Wall Street Zen raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Saturday, July 26th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $320.71.

West Pharmaceutical Services Stock Down 0.0%

WST stock opened at $246.16 on Monday. West Pharmaceutical Services has a one year low of $187.43 and a one year high of $352.33. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.08 and a current ratio of 2.78. The firm’s fifty day moving average is $230.05 and its 200 day moving average is $227.78. The firm has a market cap of $17.70 billion, a PE ratio of 36.85, a P/E/G ratio of 4.37 and a beta of 1.05.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, July 24th. The medical instruments supplier reported $1.84 EPS for the quarter, topping analysts’ consensus estimates of $1.51 by $0.33. The business had revenue of $766.50 million for the quarter, compared to analysts’ expectations of $725.11 million. West Pharmaceutical Services had a net margin of 16.48% and a return on equity of 18.43%. During the same quarter last year, the company earned $1.52 EPS. The business’s revenue was up 9.2% on a year-over-year basis.

West Pharmaceutical Services Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 19th. Shareholders of record on Wednesday, November 12th will be paid a dividend of $0.22 per share. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Wednesday, November 12th. This represents a $0.88 annualized dividend and a yield of 0.4%. West Pharmaceutical Services’s dividend payout ratio is presently 12.57%.

Institutional Investors Weigh In On West Pharmaceutical Services

Large investors have recently modified their holdings of the business. DAVENPORT & Co LLC boosted its position in West Pharmaceutical Services by 103.8% during the first quarter. DAVENPORT & Co LLC now owns 2,230 shares of the medical instruments supplier’s stock worth $499,000 after acquiring an additional 1,136 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in shares of West Pharmaceutical Services by 34.7% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 5,581 shares of the medical instruments supplier’s stock worth $1,249,000 after acquiring an additional 1,437 shares during the period. Bessemer Group Inc. boosted its holdings in West Pharmaceutical Services by 43.7% in the 1st quarter. Bessemer Group Inc. now owns 1,075 shares of the medical instruments supplier’s stock valued at $241,000 after purchasing an additional 327 shares during the last quarter. Sivik Global Healthcare LLC acquired a new position in West Pharmaceutical Services in the first quarter valued at approximately $2,799,000. Finally, State of Alaska Department of Revenue grew its holdings in shares of West Pharmaceutical Services by 2.7% during the 1st quarter. State of Alaska Department of Revenue now owns 8,486 shares of the medical instruments supplier’s stock worth $1,899,000 after purchasing an additional 225 shares during the period. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.